Senior Director, Medical Affairs

Scorpion Therapeutics; Cambridge (MA); On-site; USD 180,000 - 280,000; Full time

Job summary

Editas Medicine in Cambridge, MA seeks a Senior Director, Medical Affairs to lead strategic planning and execution for its in vivo gene editing candidate, EDIT-401, targeting LDL cholesterol reduction. You will develop medical communication strategies, build scientific platforms, and interpret complex clinical and real-world data while engaging with thought leaders and coordinating advisory boards.

This role partners with cross-functional teams to drive medical affairs initiatives across

Qualifications

• PhD/MD/PharmD with 10+ years in biopharma Medical Affairs and gene editing preferred.
• Experience with early-phase therapies and gene editing is a plus.
• Strong scientific and regulatory foundations.

Responsibilities

• Develop medical communication strategies.
• Build scientific platforms.
• Interpret complex clinical and real-world data.
• Engage with thought leaders.
• Design advisory boards.
• Support clinical trial design.
• Manage external communications.
• Build relationships with medical communities, patient organizations, and cross-functional teams.

Skills

Scientific expertise

Regulatory compliance

Stakeholder engagement

Strategic communication

Education

MD/PhD/PharmD with 10+ years in Medical Affairs

Job description

Role

Senior Director, Medical Affairs leading strategic planning and execution for Editas Medicine's in vivo gene editing candidate, EDIT-401, targeting LDL cholesterol reduction.

Responsibilities

• develop medical communication strategies
• build scientific platforms
• interpret complex clinical and real-world data
• engage with thought leaders
• design advisory boards
• support clinical trial design
• and manage external communications
• Build relationships with medical communities, patient organizations, and cross-functional teams.

Requirements

PhD, PharmD, or MD with 10+ years in biopharma Medical Affairs, preferably with early-phase therapies and gene editing.

• scientific expertise
• regulatory compliance
• stakeholder engagement
• strategic communication

High-Value

• focus on gene editing (CRISPR/Cas12a, Cas9)
• in vivo therapies
• early clinical phase
• lifecycle management
• medical communications
• KOL engagement
• advisory boards
• patient advocacy
• and cross-functional collaboration.

Work setup

Work setup and travel specifics are not detailed.